Other limitations of our study include its retrospective nature, limited sample size and a lack of a systematic TMA diagnosis strategy including ADAMTS13 activity dosage to formally exclude idiopathic TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.